Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review

References

• Akiyama Y, Fujita K, Ishida H, et al. (2012). Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab Pharmacokinet 27:325–335.
   PubMed Web of Science ®Google Scholar
• Arcamone F, Cassinelli G, Fantini G, et al. (1969). Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 11:1101–1110.
   PubMed Web of Science ®Google Scholar
• Bäckström G, Taipalensuu J, Melhus H, et al. (2003). Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci Off J Eur Fed Pharm Sci 18:359–364.
   PubMed Web of Science ®Google Scholar
• Bains OS, Karkling MJ, Grigliatti TA, et al. (2009). Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos Biol Fate Chem 37:1107–1114.
   PubMed Web of Science ®Google Scholar
• Bains OS, Karkling MJ, Lubieniecka JM, et al. (2010). Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 332:755–763.
   PubMed Web of Science ®Google Scholar
• Baker J, Ajani J, Scotté F, et al. (2009). Docetaxel-related side effects and their management. Eur J Oncol Nurs Off J Eur Oncol Nurs Soc 13:49–59.
   PubMed Web of Science ®Google Scholar
• Baker SD, Sparreboom A, Verweij J. (2006). Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45:235–252.
   PubMed Web of Science ®Google Scholar
• Balram C, Sabapathy K, Fei G, et al. (2002). Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12:81–83.
   PubMedGoogle Scholar
• Bao L, Hazari S, Mehra S, et al. (2012). Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180:2490–2503.
   PubMed Web of Science ®Google Scholar
• Bosch TM, Meijerman I, Beijnen JH, Schellens JHM. (2006a). Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285.
   PubMed Web of Science ®Google Scholar
• Bosch TM, Huitema ADR, Doodeman VD, et al. (2006b). Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res Off J Am Assoc Cancer Res 12:5786–5793.
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, et al. (2010). Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102:1003–1009.
   PubMed Web of Science ®Google Scholar
• Buda G, Maggini V, Galimberti S, et al. (2007). MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 137:454–456.
   PubMed Web of Science ®Google Scholar
• Callens C, Debled M, Delord M, et al. (2015). High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial. Breast Cancer Res Treat 153:383–389.
   PubMed Web of Science ®Google Scholar
• Chen ZS, Tiwari AK. (2011). Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. Febs J 278:3226–3245.
   PubMed Web of Science ®Google Scholar
• Chen S, Yueh MF, Bigo C, et al. (2013). Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci USA 110:19143–19148.
   PubMed Web of Science ®Google Scholar
• Chen S, Villeneuve L, Jonker D, et al. (2015). ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics 25:573–583.
   PubMed Web of Science ®Google Scholar
• Chen ZS, Furukawa T, Sumizawa T, et al. (1999). ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55:921–928.
   PubMed Web of Science ®Google Scholar
• Chew SC, Singh O, Chen X, et al. (2011). The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 67:1471–1478.
   PubMed Web of Science ®Google Scholar
• Chew SC, Sandanaraj E, Singh O, et al. (2012). Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br J Clin Pharmacol 73:606–618.
   PubMed Web of Science ®Google Scholar
• Chu XY, Kato Y, Sugiyama Y. (1997a). Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57:1934–1938.
   PubMed Web of Science ®Google Scholar
• Chu XY, Kato Y, Niinuma K, et al. (1997b). Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 281:304–314.
   PubMed Web of Science ®Google Scholar
• Colombo S, Soranzo N, Rotger M, et al. (2005). Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 15:599–608.
   PubMed Web of Science ®Google Scholar
• Conrad S, Kauffmann HM, Ito K, et al. (2002). A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321–330.
   PubMedGoogle Scholar
• Crona DJ, Ramirez J, Qiao W, et al. (2016). Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J 16:54–59.
   PubMed Web of Science ®Google Scholar
• Crouthamel MH, Wu D, Yang Z, Ho RJY. (2006). A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 95:2767–2777.
   PubMed Web of Science ®Google Scholar
• Cummings J, Anderson L, Willmott N, Smyth JF. (1991). The molecular pharmacology of doxorubicin in vivo. Eur J Cancer Oxf Engl 1990 27:532–535.
   PubMed Web of Science ®Google Scholar
• Daly AK. (2010). Genome-wide association studies in pharmacogenomics. Nat Rev Genet 11:241–246.
   PubMed Web of Science ®Google Scholar
• Database of single nucleotide polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: rs2273697, (dbSNP Build ID:147. Available from: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2273697 [last accessed 2 Aug 2016]
   Google Scholar
• Deeley RG, Westlake C, Cole SPC. (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849–899.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, Kim RB. (2012). Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249–273.
   PubMed Web of Science ®Google Scholar
• de Graan AJM, Lancaster CS, Obaidat A, et al. (2012). Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res Off J Am Assoc Cancer Res 18:4433–4440.
   PubMed Web of Science ®Google Scholar
• de Jong FA, Marsh S, Mathijssen RHJ, et al. (2004). ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res Off J Am Assoc Cancer Res 10:5889–5894.
   PubMed Web of Science ®Google Scholar
• de Jong FA, Scott-Horton TJ, Kroetz DL, et al. (2007). Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81:42–49.
   PubMed Web of Science ®Google Scholar
• De Mattia E, Toffoli G, Polesel J, et al. (2013). Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics 23:549–557.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Arbitrio M, Leone E, et al. (2011). Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther 12:780–787.
   PubMed Web of Science ®Google Scholar
• Dodds HM, Haaz MC, Riou JF, et al. (1998). Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286:578–583.
   PubMed Web of Science ®Google Scholar
• Doyle JJ, Neugut AI, Jacobson JS, et al. (2005). Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol 23:8597–8605.
   PubMed Web of Science ®Google Scholar
• Eckhoff L, Feddersen S, Knoop AS, et al. (2015). Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol Stockh Swed 54:530–537.
   PubMed Web of Science ®Google Scholar
• Fajac A, Gligorov J, Rezai K, et al. (2010). Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer 103:560–566.
   PubMed Web of Science ®Google Scholar
• Flens MJ, Zaman GJ, van der Valk P, et al. (1996). Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237–1247.
   PubMed Web of Science ®Google Scholar
• Forrest GL, Gonzalez B, Tseng W, et al. (2000). Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158–5164.
   PubMed Web of Science ®Google Scholar
• Fujita K, Nagashima F, Yamamoto W, et al. (2008). Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull 31:2137–2142.
   PubMed Web of Science ®Google Scholar
• Fujita K, Kubota Y, Ishida H, Sasaki Y. (2015). Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21:12234–12248.
   PubMed Web of Science ®Google Scholar
• Gagné JF, Montminy V, Belanger P, et al. (2002). Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608–617.
   PubMed Web of Science ®Google Scholar
• George J, Dharanipragada K, Krishnamachari S, et al. (2009). A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 9:161–165.
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741.
   PubMed Web of Science ®Google Scholar
• Gligorov J, Lotz JP. (2004). Preclinical pharmacology of the taxanes: implications of the differences. The Oncologist 2:3–8.
   Web of Science ®Google Scholar
• Glimelius B, Garmo H, Berglund A, et al. (2011). Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 11:61–71.
   PubMed Web of Science ®Google Scholar
• Grover S, Kukreti R. (2014). HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24:94–112.
   PubMed Web of Science ®Google Scholar
• Gupta E, Lestingi TM, Mick R, et al. (1994). Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723–3725.
   PubMed Web of Science ®Google Scholar
• Haenisch S, Werk AN, Cascorbi I. (2014). MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol 77:587–596.
   PubMed Web of Science ®Google Scholar
• Han B, Zhang JT. (2004). Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anti-Cancer Agents 4:31–42.
   PubMedGoogle Scholar
• Han JY, Lim HS, Yoo YK, et al. (2007). Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138–147.
   PubMed Web of Science ®Google Scholar
• Han JY, Lim HS, Shin ES, et al. (2008). Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer Amst Neth 59:69–75.
   PubMed Web of Science ®Google Scholar
• Hidemura K, Zhao YL, Ito K, et al. (2003). Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrob Agents Chemother 47:1636–1642.
   PubMed Web of Science ®Google Scholar
• Hirouchi M, Suzuki H, Itoda M, et al. (2004). Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res 21:742–748.
   PubMed Web of Science ®Google Scholar
• Ho RH, Choi L, Lee W, et al. (2007). Effect of drug transporter genotypes on pravastatin disposition in European- and African–American participants. Pharmacogenet Genomics 17:647–656.
   PubMed Web of Science ®Google Scholar
• Ho RH, Leake BF, Teft W, Kim RB. (2011). Multiple organic anion transporting polypeptides (OATPs) contribute to the in vitro and in vivo disposition of docetaxel. Cancer Res 71:4406–4406.
   Web of Science ®Google Scholar
• Hrushesky WJM. (1982). Bone marrow suppression from doxorubicin and cis-diamminedichloroplatinum is substantially dependent upon both orcadian and circannual stages of administration. Ann N Y Acad Sci 397:293–295.
   Web of Science ®Google Scholar
• Huang L, Zhang T, Xie C, et al. (2013). SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PloS One 8:e77223.
   PubMed Web of Science ®Google Scholar
• Huang Y, Penchala S, Pham AN, Wang J. (2008). Genetic variations and gene expression of transporters in drug disposition and response. Expert Opin Drug Metab Toxicol 4:237–254.
   PubMed Web of Science ®Google Scholar
• Imai Y, Nakane M, Kage K, et al. (2002). C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611–616.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Undevia SD, Iyer L, et al. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol Off J Am Soc Clin Oncol 22:1382–1388.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Kroetz DL, Schuetz E, et al. (2009). Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol Off J Am Soc Clin Oncol 27:2604–2614.
   PubMed Web of Science ®Google Scholar
• Iusuf D, Ludwig M, Elbatsh A, et al. (2014). OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice. Mol Cancer Ther 13:492–503.
   PubMed Web of Science ®Google Scholar
• Iusuf D, Hendrikx JJMA, van Esch A, et al. (2015). Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int J Cancer J Int Cancer 136:225–233.
   PubMed Web of Science ®Google Scholar
• Iyer L, Das S, Janisch L, et al. (2002a). UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43–47.
   PubMedGoogle Scholar
• Iyer L, Ramírez J, Shepard DR, et al. (2002b). Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 49:336–341.
   PubMed Web of Science ®Google Scholar
• Jada SR, Lim R, Wong CI, et al. (2007). Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C > a polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461–1467.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, et al. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513–522.
   PubMed Web of Science ®Google Scholar
• Kassner N, Huse K, Martin HJ, et al. (2008). Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos Biol Fate Chem 36:2113–2120.
   PubMed Web of Science ®Google Scholar
• Kawato Y, Aonuma M, Hirota Y, et al. (1991). Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187–4191.
   PubMed Web of Science ®Google Scholar
• Kerb R. (2006). Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4–33.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Im SA, Keam B, et al. (2015). ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 106:86–93.
   PubMed Web of Science ®Google Scholar
• Kim K, Ahn JH, Kim SB, et al. (2012). Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol 69:1221–1227.
   PubMed Web of Science ®Google Scholar
• Kitagawa C, Ando M, Ando Y, et al. (2004). Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and Irinotecan toxicity. In J Clin Oncol 22(14 Suppl):2009.
   Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Kubo M, et al. (2008). Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99:967–972.
   PubMed Web of Science ®Google Scholar
• Lakhman SS, Ghosh D, Blanco JG. (2005). Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos Biol Fate Chem 33:254–257.
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Jada SR, et al. (2007). Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8:567–575.
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Sandanaraj E, et al. (2008). Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:816–823.
   PubMed Web of Science ®Google Scholar
• Lal S, Sutiman N, Ooi LL, et al. (2016). Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics J [Epub ahead of print]. doi: 10.1038/tpj.2016.17.
   PubMed Web of Science ®Google Scholar
• Lara PN, Natale R, Crowley J, et al. (2009). Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol Off J Am Soc Clin Oncol 27:2530–2535.
   PubMed Web of Science ®Google Scholar
• Lee E, Ryan S, Birmingham B, et al. (2005). Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330–341.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Létourneau IJ, Deeley RG, Cole SPC. (2003). Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry (Mosc.) 42:5214–5224.
   Web of Science ®Google Scholar
• Létourneau IJ, Deeley RG, Cole SPC. (2005). Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 15:647–657.
   PubMed Web of Science ®Google Scholar
• Lévy P, Gligorov J, Antoine M, et al. (2013). Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 139:421–428.
   PubMed Web of Science ®Google Scholar
• Lewis LD, Miller AA, Owzar K, et al. (2013). The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29–33.
   PubMed Web of Science ®Google Scholar
• Li JZ, Tian ZQ, Jiang SN, Feng T. (2014). Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy. Genet Mol Res GMR 13:3186–3192.
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H. (2005). Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591–602.
   PubMed Web of Science ®Google Scholar
• Marcuello E, Altés A, Menoyo A, et al. (2004). UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678–682.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Tirona RG, Kim RB. (2004). Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5:273–282.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, et al. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res Off J Am Assoc Cancer Res 7:2182–2194.
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, Loos WJ, Verweij J, Sparreboom A. (2002a). Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2:103–123.
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, Verweij J, Loos WJ, et al. (2002b). Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. Br J Cancer 87:144–150.
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, Marsh S, Karlsson MO, et al. (2003). Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res Off J Am Assoc Cancer Res 9:3246–3253.
   PubMed Web of Science ®Google Scholar
• Megaraj V, Zhao T, Paumi CM, et al. (2011). Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). Pharmacogenet Genomics 21:506–515.
   PubMed Web of Science ®Google Scholar
• Michalski C, Cui Y, Nies AT, et al. (2002). A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277:43058–43063.
   PubMed Web of Science ®Google Scholar
• Minami H, Sai K, Saeki M, et al. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497–504.
   PubMed Web of Science ®Google Scholar
• Nadali F, Pourfathollah AA, Alimoghaddam K, et al. (2007). Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. Hematol Amst Neth 12:393–401.
   PubMed Web of Science ®Google Scholar
• Nigam SK. (2015). What do drug transporters really do? Nat Rev Drug Discov 14:29–44.
   PubMed Web of Science ®Google Scholar
• Nishizato Y, Ieiri I, Suzuki H, et al. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565.
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Kusuhara H, Kondo T, et al. (2007). Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322:1162–1170.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Minami H, Sugiura S, et al. (2005). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos Biol Fate Chem 33:434–439.
   PubMed Web of Science ®Google Scholar
• Okabe M, Unno M, Harigae H, et al. (2005). Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754–762.
   PubMed Web of Science ®Google Scholar
• Onoue M, Terada T, Kobayashi M, et al. (2009). UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14:136–142.
   PubMed Web of Science ®Google Scholar
• Pan YZ, Zhou A, Hu Z, Yu AM. (2013). Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos Biol Fate Chem 41:1744–1751.
   PubMed Web of Science ®Google Scholar
• Ramchandani RP, Wang Y, Booth BP, et al. (2007). The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47:78–86.
   PubMed Web of Science ®Google Scholar
• Rhodes KE, Zhang W, Yang D, et al. (2007). ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett 1:23–30.
   PubMedGoogle Scholar
• Rivory LP, Haaz MC, Canal P, et al. (1997). Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res Off J Am Assoc Cancer Res 3:1261–1266.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Spaggiari F, Indelli M, et al. (2010). Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 124:593–598.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML. (1997). Topoisomerase I inhibitors: review and update. Ann Oncol Off J Eur Soc Med Oncol ESMO 8:837–855.
   PubMed Web of Science ®Google Scholar
• Sai K, Kaniwa N, Itoda M, et al. (2003). Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13:741–757.
   PubMedGoogle Scholar
• Sai K, Saito Y, Maekawa K, et al. (2010). Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66:95–105.
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Nakamura T, Okumura K. (2003). Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397–410.
   PubMed Web of Science ®Google Scholar
• Savonarola A, Palmirotta R, Guadagni F, Silvestris F. (2012). Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J 12:277–286.
   PubMed Web of Science ®Google Scholar
• Schellens JH, Maliepaard M, Scheper RJ, et al. (2000). Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 922:188–194.
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U, et al. (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Jama 302:1429–1436.
   PubMed Web of Science ®Google Scholar
• Shang Y, Zhang Z, Liu Z, et al. (2014). miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 33:3267–3276.
   PubMed Web of Science ®Google Scholar
• Shelley M, Harrison C, Coles B, et al. (2006). Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev (4):CD005247.
   PubMedGoogle Scholar
• Shitara K, Matsuo K, Ito S, et al. (2010). Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac J Cancer Prev APJCP 11:447–452.
   PubMedGoogle Scholar
• Shou M, Martinet M, Korzekwa KR, et al. (1998). Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391–401.
   PubMedGoogle Scholar
• Shuldiner AR, O’connell JR, Bliden KP, et al. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama 302:849–857.
   PubMed Web of Science ®Google Scholar
• Singer JB, Lewitzky S, Leroy E, et al. (2010). A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42:711–714.
   PubMed Web of Science ®Google Scholar
• Sissung TM, Baum CE, Deeken J, et al. (2008). ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res Off J Am Assoc Cancer Res 14:4543–4549.
   PubMed Web of Science ®Google Scholar
• Smith NF, Acharya MR, Desai N, et al. (2005). Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4:815–818.
   PubMed Web of Science ®Google Scholar
• Soepenberg O, Dumez H, Verweij J, et al. (2005). Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 11:1504–1511.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Van Tellingen O, Scherrenburg EJ, et al. (1996). Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos Biol Fate Chem 24:655–658.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Gelderblom H, Marsh S, et al. (2004). Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin Pharmacol Ther 76:38–44.
   PubMed Web of Science ®Google Scholar
• Sprowl JA, Sparreboom A. (2014). Uptake carriers and oncology drug safety. Drug Metab Dispos Biol Fate Chem 42:611–622.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Bingham JL, Johnson D. (2009). The ABCs of human alternative splicing: a review of ATP-binding cassette transporter splicing. Curr Opin Drug Discov Devel 12:149–158.
   PubMedGoogle Scholar
• Stacy AE, Jansson PJ, Richardson DR. (2013). Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol 84:655–669.
   PubMed Web of Science ®Google Scholar
• Svoboda M, Wlcek K, Taferner B, et al. (2011). Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 65:417–426.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234.
   PubMed Web of Science ®Google Scholar
• Tagen M, Zhuang Y, Zhang F, et al. (2010). P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett 4:195–201.
   PubMedGoogle Scholar
• Tamura A, Wakabayashi K, Onishi Y, et al. (2007). Reevaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98:231–239.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Wada M, Kohno K, et al. (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129.
   PubMed Web of Science ®Google Scholar
• Teft WA, Welch S, Lenehan J, et al. (2015). OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer 112:857–865.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, et al. (2011). Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21:440–446.
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, Kim RB. (2001). Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675.
   PubMed Web of Science ®Google Scholar
• To KKW, Leung WW, Ng SSM. (2015). Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res 338:222–231.
   PubMed Web of Science ®Google Scholar
• Tran A, Jullien V, Alexandre J, et al. (2006). Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79:570–580.
   PubMed Web of Science ®Google Scholar
• Tsai SM, Lin CY, Wu SH, et al. (2009). Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta Int J Clin Chem 404:160–165.
   PubMed Web of Science ®Google Scholar
• Turrini E, Haenisch S, Laechelt S, et al. (2012). MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 22:198–205.
   PubMed Web of Science ®Google Scholar
• Ueda K, Cardarelli C, Gottesman MM, Pastan I. (1987). Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 84:3004–3008.
   PubMed Web of Science ®Google Scholar
• Van Poppel H. (2005). Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Can J Urol 1:81–85.
   Google Scholar
• van Zuylen L, Verweij J, Nooter K, et al. (2000). Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res Off J Am Assoc Cancer Res 6:2598–2603.
   PubMed Web of Science ®Google Scholar
• Voon PJ, Yap HL, Ma CYT, et al. (2013). Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. Br J Clin Pharmacol 75:1497–1505.
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, et al. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754–3762.
   PubMed Web of Science ®Google Scholar
• Woodahl EL, Yang Z, Bui T, et al. (2004). Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 310:1199–1207.
   PubMed Web of Science ®Google Scholar
• Woodahl EL, Crouthamel MH, Bui T, et al. (2009). MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol 64:183–188.
   PubMed Web of Science ®Google Scholar
• Xiang X, Jada SR, Li HH, et al. (2006). Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 16:683–691.
   PubMed Web of Science ®Google Scholar
• Yang T, Zheng ZM, Li XN, et al. (2013). MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med 238:1024–1032.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wu D, Bui T, Ho RJY. (2008). A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther 327:474–481.
   PubMed Web of Science ®Google Scholar
• Yao S, Sucheston LE, Zhao H, et al. (2014). Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241–247.
   PubMed Web of Science ®Google Scholar
• Yin JY, Huang Q, Yang Y, et al. (2009). Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 19:206–216.
   PubMed Web of Science ®Google Scholar
• Yu AM, Tian Y, Tu MJ, et al. (2016). MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy. Drug Metab Dispos Biol Fate Chem 44:308–319.
   PubMed Web of Science ®Google Scholar
• Zamber CP, Lamba JK, Yasuda K, et al. (2003). Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19–28.
   PubMedGoogle Scholar
• Zamboni WC, Ramanathan RK, McLeod HL, et al. (2006). Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs 24:393–401.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li W, Zhu D, et al. (2014). Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol Northwood Lond Engl 31:802.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Sparreboom A, Tan EH, et al. (2005). Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 59:415–424.
   PubMed Web of Science ®Google Scholar
• Taxane pathway, pharmGKB, pharmacokinetics PharmGKB. Available from: http://www.pharmgkb.org/pathway/PA154426155 [last accessed 8 Jan 2016].
   Google Scholar